[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sara Refaat Azab Metry\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100654011","phase-1-effect-of-trimetazidine-on-endothelin-1-and-clinical-outcomes-of-patients-with-diabetic-peripheral-neuropathy-100654011",false,"NCT07794475","Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy","Inclusion criteria:\n\n* Males or females aged 18-65 years diagnosed with Type 2 Diabetes.\n* Regular attendance of the outpatient diabetes clinic of national institute of diabetes to ensure adequate follow up, glycemic control and monitor any complication or side effect.\n* Patients diagnosed with Diabetic Neuropathy (by pinprick, temperature, ankle reflex, and vibration perception (128-Hz tuning fork) or pressure sensation (10 g monofilament test).\n* Glycated Hgb more than 7%\n\nExclusion criteria:\n\n* Patients with autoimmune disorders (Sjogren's syndrome, lupus, rheumatoid arthritis), inherited disorders causing peripheral neuropathy, thyroid diseases, chronic inflammatory demyelinating polyneuropathy, patients undergoing gastroplasty surgery, and cancer patients.\n* Patients have Parkinson disease or any motor movement disorders\n* Any clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or other endocrine disease.\n* Pressure on or injury to the nerves\n* Patients with kidney (eGFR less than 30 ml\u002Fmin) or severe liver dysfunction (ALT more than 3x ULN).\n* Patients with recent history of infection.\n* Patients with cerebral vascular disease, vasculitis, toxic neuritis, spondyloarthropathy, foot edema or ulcer and diagnosis of other neuromuscular disorders or neurodegenerative diseases.\n* Use of medications or supplements known to cause peripheral neuropathy.\n* Patients consuming alcohol, any antioxidant supplements or anti-inflammatory medicines and drug abuse.\n* Ketoacidosis or hypoglycemia resulting in hospital admission within the last 3 months.\n* Pregnancy or lactation.\n* Medical, psychological, behavioral or pharmacological factors interfering with the ability to participate in a trial.\n* Any known allergy to Trimetazidine","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to investigate if trimetazidine can improve clinical outcomes of patients with diabetic peripheral neuropathy. The main questions it aims to answer are:\n\nDoes trimetazidine improve the symptoms of diabetic peripheral neuropathy? Does trimetazidine affect endothelin-1 levels?\n\nParticipants in the interventional arm will receive trimetazidine tablets 35 mg twice daily for three months.",[27],"Diabetic Peripheral Neuropathic Pain (DPN)","RECRUITING","2026-08-27",{"date":31,"type":32},"2026-08-31","ACTUAL",{"date":34,"type":32},"2026-08-01",{"date":36,"type":20},"2027-02",{"name":38,"class":39},"Sara Refaat Azab Metry","OTHER",""]